Volume is actually very modest. While the SP is down, I am not getting the sense that long term SHs are dumping the stock. I think if you have been following this company, it is clear that it is a very suitable strategic acquisition for a mid market pharmaceutical company. At current SP, not much to lose and very attractive upside. As many have said before, it is a binary investment with much of the downside mitigated by the demonstrated efficacy and safety of PRO 140.
News 
Market Data 
Discover 
